Latest news about Gaudium IVF & Women Health
Gaudium IVF & Women Health
116.90
-0.66(-0.56%)
Company Performance:
View Company Insights1D-0.56%
1M+4.01%
6M+45.65%
1Y+45.65%
5Y+45.65%
More news about Gaudium IVF & Women Health
23May 26
NCLT Rejects Insolvency Petition Against Gaudium IVF
NCLT New Delhi rejected an insolvency petition filed by Ramaa Capital against Gaudium IVF and Women Health Limited on May 15, 2026. The company received the order on May 22, 2026, confirming no impact on its financial or operational activities.
16Apr 26
Gaudium IVF and Women Health Limited Clarifies Share Price Movement is Market Driven
Gaudium IVF and Women Health Limited clarified to BSE and NSE on April 16, 2026, that recent share price movements are purely market driven. The company confirmed no undisclosed price sensitive information exists and reaffirmed commitment to timely disclosure of material events under SEBI regulations.
15Apr 26
Gaudium IVF and Women Health Limited Updates Corporate Identification Number Following Stock Exchange Listing
Gaudium IVF and Women Health Limited has updated its Corporate Identification Number from 'U85100DL2015PLC278296' to 'L85100DL2015PLC278296' following its equity shares listing on NSE and BSE. The company's status has been changed from 'Unlisted' to 'Listed' in MCA records. Incorporated in 2015, the company operates with authorized capital of ₹44,00,00,000 and paid-up capital of ₹36,39,34,420, maintaining active compliance status under the leadership of promoter directors Manika Khanna and Peeyush Khanna.
10Apr 26
Gaudium IVF and Women Health Limited Files Compliance Certificate for Q4FY26 Under SEBI Regulations
Gaudium IVF and Women Health Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) on April 10, 2026. The company's registrar, Bigshare Services Private Limited, confirmed the regulation's non-applicability due to complete share dematerialization with no rematerialization or dematerialization requests during the quarter ended March 31, 2026.
08Apr 26
Gaudium IVF Submits Additional Arbitration Disclosures Following BSE Query
Gaudium IVF & Women Health Limited provided comprehensive disclosures following BSE's query on arbitration proceedings involving ₹29.21 crore claim by Neomile Corporate Advisory. Bombay High Court appointed Justice Nitin Jamdar as sole arbitrator on April 02, 2026, with company explaining disclosure delay due to weekend court order upload.
02Apr 26
Gaudium IVF Launches AI-Led Infertility Treatment in Industry-First Initiative
Gaudium IVF and Women Health Limited has launched AI-led infertility treatment in an industry-first initiative for India. The company has integrated advanced AI-driven embryology systems SiD and ERICA into clinical practice through collaboration with UK-based IVF 2.0. The milestone was inaugurated by Union Minister Shri Nitin Jairam Gadkari on April 1st, 2026, with early observations suggesting significant improvements in fertilisation and blastocyst development rates.
19Mar 26
Gaudium IVF And Women Health Claims Significant Growth Potential In India's Fertility Care Sector
Gaudium IVF And Women Health claims significant growth potential in India's fertility care sector and aims to establish leadership through expanded access and improved outcomes. The company is focusing on building a trusted fertility network to serve the growing demand for specialized reproductive health services across the country.
19Mar 26
Gaudium IVF Reports Q3 FY26 Revenue of ₹245.07 Crores in First Post-IPO Results
Gaudium IVF & Women Health Limited announced strong Q3 FY26 results with consolidated revenue of ₹245.07 crores showing 70.19% year-over-year growth and net profit of ₹36.31 crores. The results mark the company's first earnings announcement following its successful IPO completion and listing on NSE and BSE on February 27, 2026, after raising approximately ₹1,650.01 crores.
18Mar 26
Gaudium IVF Appoints New Internal and Secretarial Auditors for FY 2025-26
Gaudium IVF and Women Health Limited appointed M/s. Ram Rattan & Associates as Internal Auditors and M/s. Suresh Nainwal & Company as Secretarial Auditors for FY 2025-26. The appointments were approved during a board meeting on March 18, 2026, based on Audit Committee recommendations and comply with SEBI regulations.
Industry Peers
Dr. Lal Path Labs
Vijaya Diagnostic Centre
Metropolis Healthcare
Thyrocare Technologies
Nephrocare Health Services
Krsnaa Diagnostics
Suraksha Diagnostic
One Global Service Provider
3B BlackBio DX
Health X Platform
1,645.70
(-0.28%)
1,365.20
(-2.33%)
556.00
(+2.15%)
555.60
(-0.29%)
671.95
(-0.44%)
562.85
(-1.75%)
273.55
(+1.60%)
583.40
(-5.00%)
1,173.50
(-2.68%)
312.25
(-0.83%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
